Ordering
Available Variants5 mg
CHA.64631-5mg
Price
€178.40
Available – Dispatch in 14 days
25 mg
CHA.64631-25mg
Price
€708.00
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.64631-5mg | €178.40 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.64631-25mg | €708.00 |
≥98% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C29H44F2N6O2 |
|---|---|
| CAS Number | 1481677-78-4 |
| Molecular Weight | 546.70 |
| NACRES | NA.77 |
| PubChem Substance ID | 329825635 |
| UNSPSC Code | 51111800 |
| MDL number | MFCD28044322 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
UNC0642, also known by its CAS number 1481677-78-4, is a potent and selective inhibitor of G9a and GLP histone methyltransferases. This compound has been shown to effectively suppress the activity of these enzymes, which are involved in the regulation of gene expression through histone methylation. By inhibiting G9a and GLP, UNC0642 has been found to induce changes in the methylation status of histones, leading to alterations in chromatin structure and gene expression. As a result, UNC0642 has been investigated as a potential therapeutic agent for the treatment of various diseases, including cancer, where dysregulation of histone methylation has been implicated in disease progression. Further research is needed to fully explore the potential of UNC0642 as a therapeutic agent and to understand its mechanisms of action in different disease contexts.
